# US 2024/0390388 A1 · Tricyclic compounds and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390388 A1
- Document ID: US20240390388A1
- Status: Published application
- Kind: A1
- Application number: 18/262,724
- Filed: 2022-01-25
- Published: 2024-11-28
- Earliest claimed: 2021-01-29
- Assignees: Medshine Discovery Inc.
- Applicants: Medshine Discovery Inc.
- Inventors: Jingjie HUANG; Tao YU; Ye TAN; Chengde WU; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20240390388A1

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- C07D 498/04: Ortho-condensed systems
- C07D 498/10: Spiro-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A series of tricyclic compounds and the use thereof. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound of formula (II) or a pharmaceutically acceptable salt thereof,
wherein
T is selected from O and S;
R1 is selected from —C1-3 alkyl- and —C1-3 alkyl-cyclopropyl-;
R1 is selected from H and C1-3 alkyl, and the C1-3 alkyl is optionally substituted by 1, 2, or 3 Ra;
R2 is selected from H, F, Cl, Br, I, OH, and C1-3 alkyl, and the C1-3 alkyl is optionally substituted by 1, 2, or 3 Rb;
X and Y are each independently selected from O and NR3, and X and Y are not selected from O at the same time;
R3 is independently selected from H, OH, CN, C1-3 alkyl, C1-3 alkoxy, and —O-C3-5 cycloalkyl, and the C1-3 alkyl, C1-3 alkoxy, and —O-C3.5 cycloalkyl are optionally substituted by 1, 2, or 3 Rc;
R4 and R5 are selected from H, F, Cl, Br, I, OH, and C1-3 alkyl;
R6 is selected from H and C1-3 alkyl;
R7 is selected from C1-3 alkyl, C1-3 alkoxy, and 3- to 5-membered heterocycloalkyl;
or, R6, R7 together with the carbon atom they share form a 3- to 5-membered heterocycloalkyl;
or, R1, R7 together with the atom to which they are attached form a 3- to 5-membered heterocycloalkyl;
ring B is selected from 4- to 8-membered heterocycloalkyl, and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1, 2, or 3 Rd;
Ra, Rb, Rc, and Rd are each independently selected from F, Cl, Br, and I.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is selected from H and CH3, and the CH3 is optionally substituted by 1, 2, or 3 Ra.

### Claim 3 (depends on 2)

The compound or the pharmaceutically acceptable salt thereof according to claim 2, wherein R1 is selected from H, CH3, CH2F, CHF2, and CF3.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R2 is selected from H, F, Cl, Br, I, OH, and CH3, and the CH3 is optionally substituted by 1, 2, or 3 Rb.

### Claim 5 (depends on 4)

The compound or the pharmaceutically acceptable salt thereof according to claim 4, wherein R2 is selected from H, F, Cl, Br, I, OH, CH3, CH2F, CHF2, and CF3.

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is independently selected from H, OH, CN, CH3, CH2CH3, OCH3, OCH2CH3, —OCH(CH3)2, —O-cyclopropyl, and —O-cyclobutyl, and the CH3, CH2CH3, OCH3, OCH2CH3, —OCH(CH3)2, —O-cyclopropyl, and —O-cyclobutyl are optionally substituted by 1, 2, or 3 Rc.

### Claim 7 (depends on 6)

The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein R3 is independently selected from H, OH, CN, CH3, CH2CH3, OCH3, OCH2CH3, —OCH(CH3)2, —O-cyclopropyl, and —O-cyclobutyl.

### Claim 8 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein X and Y are each independently selected from O, NH, NOH, NCN, N—CH3, N—OCH3, N—OCH2CH3, N—OCH(CH3)2, N—O-cyclopropyl, and N—O-cyclobutyl.

### Claim 9 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R4 and R5 are selected from H, F, Cl, Br, I, OH, and CH3.

### Claim 10 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R7 is selected from CH3, CH (CH3)2, OCH3, and oxetanyl.

### Claim 11 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R6, R7 together with the carbon atom they share form an oxetanyl.

### Claim 12 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1, R7 together with the atom to which they are attached form an azetidinyl and a pyrrolidinyl.

### Claim 13 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein L is selected from —CH2CH2—, —CH(CH3)CH2—, and

### Claim 14 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring B is selected from
and the
are optionally substituted by 1, 2, or 3 Rd.

### Claim 15 (depends on 14)

The compound or the pharmaceutically acceptable salt thereof according to claim 14, wherein ring B is selected from

### Claim 16 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, selected from

### Claim 17 (depends on 16)

The compound or the pharmaceutically acceptable salt thereof according to claim 16, selected from

### Claim 18

A compound of the following formula or a pharmaceutically acceptable salt thereof, selected from

### Claim 19 (depends on 18)

The compound or the pharmaceutically acceptable salt thereof according to claim 18, selected from

### Claim 20 (depends on 1)

A method for inhibiting PI3Kα kinase in a subject in need thereof, comprising administering the compound of formula (II) or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.
